Dr. Jordi Bruix on Efficacy and Safety of Regorafenib in HCC After Sorafenib
November 17th 2016Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the efficacy, safety, and quality-of-life with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA for second-line systemic therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib.
Dr. Ghassan Abou-Alfa on Impact of Second-Line Regorafenib in HCC
November 17th 2016Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the impact of the phase III RESORCE trial, which demonstrated that regorafenib improved survival over placebo for patients with hepatocellular carcinoma (HCC) that progressed on sorafenib.
Dr. Montano-Loza on Link Between HCC Risk and High Visceral Adipose Tissue
November 15th 2016Aldo J. Montano-Loza, MD, MSc, PhD, associate professor of medicine, program director of hepatology, gastroenterology rotation supervisor, University of Alberta, discusses the link between high visceral adipose tissue and hepatocellular carcinoma risk in patients with cirrhosis.
Dr. Naveed Zafar Janjua on Impact of Hepatitis C Treatment Timing on HCC Risk
November 15th 2016Naveed Zafar Janjua, MBBS, MSc, DrPH, senior scientist, clinical prevention services, BC Centre for Disease Control and clinical associate professor, School of Population and Public Health, University of British Columbia, discusses the findings from the British Columbia hepatitis testers cohort, which looked at the impact of hepatitis infection on long term risk of hepatocellular carcinoma (HCC).
Preclinical Studies Help to Illuminate Immunotherapy's Role in HCC
November 14th 2016Following on their impressive success in the treatment of several other tumor types, immune-based therapies are being studied in clinical trials for hepatocellular carcinoma and are showing promising signals of efficacy.
Lack of Screening, Surveillance Leads to Rising HCC Rates in Hepatitis B Patients
November 13th 2016Hepatocellular carcinoma‎ incidence continues to rise among patients with hepatitis B despite improvements in antiviral therapies, stressing the importance of screening and surveillance in this population.
Dr. George N. Ioannou on the Efficacy of Antiviral Agents for Hepatitis C in HCC Patients
November 13th 2016George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC).
Dr. Gonzalez on Cost-Benefit of Treating Hepatitis C in HCC Patients Before Transplant
November 13th 2016Stevan A. Gonzalez, MD MS, clinical assistant professor, department of internal medicine, Texas A&M College of Medicine, medical director of liver transplantation, Simmons Transplant Institute, Baylor All Saints Medical Center, discusses a cost effectiveness analysis of treating hepatitis C patients with hepatocellular carcinoma (HCC) before or after a liver transplant.